Singapore markets close in 26 minutes

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
53.84-0.01 (-0.02%)
At close: 4:00PM EDT

Emergent BioSolutions Inc.

400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
240 631 3200

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees2,200

Key executives

NameTitlePayExercisedYear born
Mr. Fuad El-HibriFounder & Exec. Chairman1.2M9.68M1958
Mr. Robert G. KramerCEO, Pres & Exec. Director2.13MN/A1957
Mr. Richard S. LindahlExec. VP, CFO & Treasurer1.02MN/A1964
Mr. Adam R. HaveyExec. VP & COO1M1.44M1971
Mr. Atul SaranExec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel983.57kN/A1973
Mr. Howard AndersonSr. VP & Chief Information OfficerN/AN/AN/A
Mr. Robert G. BurrowsVP of Investor RelationsN/AN/AN/A
Ms. Lynn KiefferVP of Corp. CommunicationsN/AN/AN/A
Ms. Nina DeLorenzoSr. VP of Global Communications & Public AffairsN/AN/AN/A
Ms. Katherine StreiExec. VP of HR & Chief HR OfficerN/AN/A1962
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; and Trobigard, a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG for the treatment of SARS-CoV-2; FLU-IGIV for the treatment of seasonal influenza A virus; AV7909, an anthrax vaccine candidate; CHIKV VLP, a chikungunya virus VLP vaccine; ZIKV-IG, a zika therapeutic candidate; Shigella-ETEC, a shigella vaccine expressing ETEC antigens; EBS-LASV, a vector vaccine for Lassa fever; UNI-FLU, a universal influenza vaccine; rVSV-Marburg, a vector vaccine for treatment of Marburg virus disease; rVSV-Sudan, a vector vaccine for treatment of Sudan virus disease; DAT, a diphtheria antitoxin; Ricin-IG, a ricin antitoxin; and Pan-Ebola, a Ebola/Sudan monoclonal. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate governance

Emergent BioSolutions Inc.’s ISS governance QualityScore as of 1 July 2021 is 6. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 7; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.